

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS LLC AND  
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,  
Petitioners,

v.

ALMIRALL, LLC  
Patent Owner.

---

Case IPR2018-00608  
Patent No. 9,161,926 B2

---

**PATENT OWNER'S SUR-REPLY**

## TABLE OF CONTENTS

	Page
I. INTRODUCTION .....	1
II. PETITIONER DOES NOT DISPUTE THE PROPER CONSTRUCTION OF "DAPSONE" IN THE '926 PATENT .....	3
III. PETITIONER FAILS TO SHOW ITS ASSERTED ART RENDERS OBVIOUS THE CHALLENGED CLAIMS OF THE '926 PATENT.....	6
A. Petitioner Fails to Show Motivation to Develop a New Dapsone Formulation .....	6
B. Petitioner Fails to Show Motivation in Garrett to Use an Increased Dapsone Concentration of 7.5% .....	7
C. Petitioner Does Not Dispute that Garrett Provides No Motivation or Teaching to Use Acrylamide/Sodium Acryloyldimethyl Taurate Copolymer as the Polymeric Viscosity Builder .....	10
D. Petitioner Does Not Dispute that Garrett Provides No Motivation or Teaching to Exclude Adapalene.....	10
E. Petitioner Fails to Show that the Asserted Art Discloses the Claimed About 2% w/w to About 6% w/w of a Polymeric Viscosity Builder Consisting of Acrylamide/Sodium Acryloyldimethyl Taurate Copolymer .....	11
F. Petitioner Fails to Show Motivation to Combine .....	17
1. Petitioner Fails to Show Motivation to Combine Garrett and Nadau-Fourcade (Ground 1) .....	17
2. Petitioner Fails to Show Motivation to Combine Garrett and Bonacucina (Ground 2).....	19
IV. CONCLUSION.....	20

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>CASES</b>	
<i>Almirall LLC v. Taro Pharm. Indus. Ltd.</i> , No. 1:17-cv-00663-JRB-SRF (D. Del. June 1, 2017) .....	2
<i>Markman v. Westview Instruments, Inc.</i> , 52 F.3d 967 (Fed. Cir. 1995) (en banc) .....	15
<i>Multilayer Stretch Cling Film Holdings, Inc. v. Berry Plastics Corp.</i> , 831 F.3d 1350 (Fed. Cir. 2016) .....	14
<i>Phillips v. AWH Corp.</i> , 415 F.3d 1303 (Fed. Cir. 2005) .....	16
<i>Shire Dev., LLC v. Watson Pharm., Inc.</i> , 848 F.3d 981 (Fed. Cir. 2017) .....	14
<i>Thorner v. Sony Computer Entm't Am. LLC</i> , 669 F.3d 1362 (Fed. Cir. 2012) .....	3
<i>Upsher-Smith Labs., Inc. v. Pamlab, L.L.C.</i> , 412 F.3d 1319 (Fed. Cir. 2005) .....	10, 11
<i>Vitronics Corp. v. Conceptronic, Inc.</i> , 90 F.3d 1576 (Fed. Cir. 1996) .....	15
<b>STATUTES</b>	
35 U.S.C. § 312(a) .....	8

**PATENT OWNER'S EXHIBIT LIST**

<b>Exhibit No.</b>	<b>Description</b>
2001	Patent Assignment Agreement dated October 10, 2018
2002	Hagan declaration in support of <i>pro hac vice</i> application
2003	Declaration of Professor Alexander M. Klibanov
2004	<i>Curriculum Vitae</i> for Professor Alexander M. Klibanov
2005	International Patent Application Publication No. WO 2011/014627 ("Ahluwalia")
2006	International Patent Application Publication No. WO 2009/108147 ("Garrett I")
2007	International Patent Application Publication No. WO 2010/105052 ("Hani")
2008	U.S. Patent No. 4,829,058 ("Seydel I")
2009	U.S. Patent No. 4,912,112 ("Seydel II")
2010	Wayback Machine Results for David Pascoe, <i>Aczone Fails to Impress for Rosacea</i> , Rosacea Support Group (July 23, 2012), available at <a href="https://rosacea-support.org/aczone-fails-to-impress-for-rosacea.html">https://rosacea-support.org/aczone-fails-to-impress-for-rosacea.html</a>
2011	S. Puavilai <i>et al.</i> , "Incidence of anemia in leprosy patients treated with dapsone," J. Med. Assoc. Thailand 67(7): 404-407 (1984) ("Puavilai")

Exhibit No.	Description
2012	World Health Organization Alert No. 117, Antimalarial chlorproguanil-dapsone (LapDap™) withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (Dacart™) versus artemether-lumefantrine (Coartem®) and confirmation of findings in a comparative trial of LapDap™ versus Dacart™ (Mar. 4, 2008)
2013	MaryAnn Steiner, “Dapsone Topical Gel for Acne,” J. Pharm. Soc. Wisc. 12(6): 67–71 (2009) (“Steiner”)
2014	ACZONE™ Gel, 5% Prescribing Information (2008) (“2008 Aczone 5% PI”)
2015	Robert Lott <i>et al.</i> , “Medication adherence among acne patients: A review.” J. Cosmetic Dermatology 9: 160–166 (2010) (“Lott”)
2016	Kirk A. James <i>et al.</i> , “Emerging drugs for acne,” Expert Opin. Emerging Drugs 14(4): 649–659 (2009) (“James I”)
2017	Barry Coutinho, “Dapsone (Aczone) 5% Gel for the Treatment of Acne,” American Family Physician (Dec. 2010) (“Coutinho”)
2018	Food and Drug Administration Inactive Ingredient Database (September, 2012)
2019	H.C. Korting & C. Schöllmann, “Current topical and systemic approaches to treatment of rosacea,” JEADV 23: 876–882 (2009) (“Korting”)
2020	European Commission’s Scientific Committee on Consumer Safety, Opinion on Diethylene Glycol Monoethyl Ether (DEGEE) (2010)
2021	Food and Drug Administration Inactive Ingredient Database (December, 2012)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.